top of page
Bill Massey.jpg

Bill W. Massey,

Executive Vice-President, Regulatory Affairs

Bill W. Massey, Ph.D., Executive Vice-President, Regulatory Affairs


Dr. Massey is a neuropharmacologist, pharmacogeneticist, life sciences professional, senior executive and entrepreneur. Dr. Massey received his Ph.D. in Pharmacology at the University of Arkansas for Medical Sciences and subsequently was an investigator at the Pritzker School of Medicine’s Drug Abuse Research Center at The University of Chicago. Dr. Massey holds long-standing adjunct faculty appointments at the University of Arkansas for Medical Sciences (Associate Professor, Dept. of Pharmacology and Interdisciplinary Toxicology) and the University of Mississippi Medical Center (Clinical Assistant Professor, Dept. of Psychiatry). 

Dr. Massey has previously held leadership positions at Merck, Astra Merck, Quintiles, Scirex, Astra Zeneca, Scientific Commercialization, Litmus Molecular Design, SureGene, and GeneAlign. He has played a leadership role placing  28 new drugs into human testing and  in bringing 8 new drugs onto the market.  Dr. Massey held the Jack Martin, MD Research Professorship in Psychopharmacology at Vanderbilt University, where he conducted research into the genetics, biological basis and pharmacological treatment of schizophrenia and serious mental illness in collaboration with Dr. Herbert Y. Meltzer.  Dr. Massey has also served as Chief Science Officer at Opiate Treatment Centers of America.  In addition to his position with CadiraMD, Dr. Massey is currently a Visiting Scholar at the Feinberg School of Medicine’s Dept. of Psychiatry and Human Behavior at Northwestern University where he continues his research collaboration with Dr. Meltzer.

bottom of page